The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.
Makers of medical device implants and diagnostic products proved health care was no monolith after broadly outperforming the U.S. market and their health care brethren in 2018. But 2019 is shaping up quite differently through the first day of trading amid a spotlight from a variety of investment banks.
Increasing wariness in Washington over China’s investments in U.S. biotechnology companies may cool a hot source of capital for medical startups.
As Biogen Inc. prepares to kick off earnings season Tuesday for a beaten-down large-cap biotechnology sector, investors won’t be too focused on the financial results.
On Thursday the major markets closed in green zone again. DJIA +0.73%, Nasdaq +0.57%, S&P500 +0.53%! Biotech market also has raised: NASDAQ Biotechnology (NBI) +0.33%! Shares of Prothena Corporation plc (PRTA) +5.02% and Foamix Pharmaceuticals Ltd (FOMX) +7.12% had raised. Shares of Immune Desi (IMDZ) -6.53% and XBiotech Inc. (XBIT) -15.49% had fallen! Sage Therapeutic (SAGE) stocks increased $0.45 and closed at $6.77 (+7.12%). The trading volume exceeded 5 times the average trading: 534K vs. 164K. The company's capitalization was $208M. The minimum FOMX share price: $5.48, while the maximum price: $12.20.